Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $43 to $22.
August 12, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Pacira BioSciences but lowers the price target from $43 to $22.
The lowered price target from $43 to $22 suggests a significant reduction in the analyst's expectations for the stock's performance, which could negatively impact investor sentiment in the short term despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100